INTERCEPT® Blood System USA’s Post

We recently met with Dr. Jerry E. Squires to discuss blood safety and the role of INTERCEPT treated platelets at the Medical University of South Carolina. “PR (pathogen-reduced) platelets provide a higher margin of safety through reduced bacterial contamination, viral and emerging infectious risk as well as reduced risk in inadvertently transfusing an unirradiated product. This is particularly important for our hematology-oncology patients who require large quantities of platelets and are exposed to many donors.” – Jerry E. Squires, M.D., PhD Medical Director of Transfusion Service Professor of Pathology and Transfusion Medicine Medical University of South Carolina Learn more about why hospitals like the Medical University of South Carolina use INTERCEPT treated platelets: hcp.intercept-usa.com #Cerus #INTERCEPT #pathogeninactivation #platelets #JOINTHEMOVEMENT CONTRAINDICATIONS Contraindicated for preparation of platelet components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens. Contraindicated for preparation of platelet components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth less than 375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen. WARNINGS AND PRECAUTIONS Only INTERCEPT Processing Sets for platelets are approved for use in the INTERCEPT Blood System. Use only the INTERCEPT INT100 Illuminator for UVA illumination of amotosalen-treated platelet components. No other source of UVA light may be used. Please refer to the Operator’s Manual for the INT100 Illuminator. Discard any platelet components not exposed to the complete INT100 illumination process. Tubing components and container ports of the INTERCEPT Blood System contain polyvinyl chloride (PVC). Di(2-ethylhexyl)phthalate (DEHP) is known to be released from PVC medical devices, and increased leaching can occur with extended storage or increased surface area contact. Blood components will be in contact with PVC for a brief period of time (approx. 15 minutes) during processing. The risks associated with DEHP released into the blood components must be weighed against the benefits of therapeutic transfusion. © 2024 Cerus Corporation. Cerus, INTERCEPT, and the Cerus logo are registered trademarks of Cerus Corporation. MKT-EN 00685-49 v1.0

To view or add a comment, sign in

Explore topics